Humana's (HUM) Q4 results have left many investors with "questions around just how long the Stars turnaround will take outside of the ongoing [payment year 2026] litigation," Morgan Stanley said in a note to clients on Wednesday.
The investment firm highlighted the fact that there was "no color on when Stars litigation outcome is expected."
In October, Humana started legal action against the US Department of Health and Human Services and the Centers for Medicare and Medicaid Services over the 2025 Medicare Advantage's Star Ratings assigned to its plans, according to media reports.
"The Stars overhang remains a key swing factor in [Humana's] timeline to achieve target [Medicare Advantage] margins," Morgan Stanley said in the note.
The investment firm said it's reiterating "prior assumptions on the potential Stars headwind in 2026, which could amount to an unmitigated -126% headwind to EPS."
Morgan Stanley cut Humana's price target to $285 from $301 and kept the company's equal-weight rating, citing "persistent uncertainty."
Price: 265.99, Change: +8.65, Percent Change: +3.36
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。